SCHEMBL8488608

SCHEMBL8488608

COC(=O)N1CCN(C(=O)C(C)Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 19/20 0.58
ERBB2 P04626 8/20 0.58
HPGD P15428 1/20 0.58
HTT P42858 1/20 0.58
MAPT P10636 1/20 0.47
ERBB4 Q15303 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
AURKA O14965 1/20 0.42
INSR P06213 1/20 0.42
FBP1 P09467 1/20 0.42
PDGFRB P09619 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
CLK1 P49759 1/20 0.42
EPHB4 P54760 1/20 0.42
TEK Q02763 1/20 0.42
AURKB Q96GD4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6994929 0.92 EGFR (0.60) EGFRERBB2HPGDHTTMAPT
SCHEMBL6997525 0.92 EGFR (0.67) EGFRERBB2HPGDHTTMAPT
SCHEMBL6995214 0.92 EGFR (0.59) EGFRERBB2HPGDHTTMAPT
SCHEMBL8486621 0.90 EGFR (0.57) EGFRERBB2HPGDHTTMAPT
SCHEMBL6997165 0.90 EGFR (0.57) EGFRERBB2HPGDHTTMAPT
SCHEMBL6986980 0.90 EGFR (0.57) EGFRERBB2HPGDHTTMAPT
SCHEMBL6998518 0.86 EGFR (0.56) EGFRERBB2HPGDHTTMAPT
SCHEMBL6991387 0.85 EGFR (0.77) EGFRERBB2HPGDHTTMAPT
SCHEMBL8487002 0.85 EGFR (0.59) EGFRERBB2HPGDHTTMAPT
SCHEMBL6990908 0.84 EGFR (0.58) EGFRERBB2HPGDHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5977102-A INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; DR. KARL THOMAE GMBH (DE) 1999-11-02 US disclosed